Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT01706289 |
| Other study ID # |
NTUH20090323HRV |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
October 10, 2012 |
| Last updated |
October 12, 2012 |
| Start date |
March 2009 |
| Est. completion date |
May 2014 |
Study information
| Verified date |
September 2012 |
| Source |
National Taiwan University Hospital |
| Contact |
Ying-Chuen Lai |
| Phone |
886-02-23123456 |
| Email |
ying.chuen[@]msa.hinet.net |
| Is FDA regulated |
No |
| Health authority |
Taiwan: Department of Health |
| Study type |
Observational
|
Clinical Trial Summary
Exploring the relationship between serum VAP-1 and cardiovascular autonomic neuropathy in
subjects with type 2 diabetes mellitus
Description:
The prevalence of diabetes mellitus is increasing recently, especially in the urban area of
developing countries. Subjects with diabetes have higher rate of hospitalization and have
higher mortality. Diabetes results in various complications including diabetic retinopathy,
nephropathy, neuropathy, and cardiovascular complications. Among these, cardiovascular
autonomic neuropathy is one of clinical important complication of diabetes. Diabetic
subjects with reduced cardiovascular autonomic function have been shown to strongly
associate with an increased risk of silent myocardial ischemia and increased mortality. They
also have higher risk of sudden death, intraoperative and perioperative cardiovascular
instability. Formation of advanced glycation end product (AGE) and oxidative stress are
important causes of diabetic neuropathy. Vascular adhesion protein-1 (VAP-1), an adhesion
molecule with an activity of semicarbazide-sensitive amine oxidases (SSAO), which can
catalyze endogenous amines to produces corresponding aldehydes, H2O2, and ammonia. We have
demonstrated that serum VAP-1 is a source of systemic AGE and oxidative stress, and is
associated with nephropathy and atherosclerosis. There are reports demonstrating that
subjects with diabetic retinopathy or stroke have higher serum VAP-1. To our best knowledge,
there is no report regarding the relationship between serum VAP-1 and neuropathy. In present
study, we will measure serum VAP-1 and check cardiovascular autonomic function. We will also
explore the relationship between serum VAP-1 and cardiovascular autonomic neuropathy in
subjects with type 2 diabetes mellitus.
